APRINOIA Therapeutics and Ross Acquisition II mutually terminated the $280m merger.

APRINOIA Therapeutics, a clinical-stage biotechnology company focused on neurodegenerative diseases, and Ross Acquisition II, a special purpose acquisition company, mutually terminated the $280m merger. The parties entered into a Termination Agreement on August 21, 2023, which is effective immediately and contains mutual releases for claims and liabilities.